Clinical And Regulatory RisksRisks include failure of biosimilar candidates in clinical trials, failure to secure regulatory approval, failure to achieve commercial success due to market size, penetration rate, and competition, and potential dilution risk.
Financial PerformanceTotal revenue was €5.3M, missing our projection of €14.0M.
Market ChallengesU.S. marketing of FYB201 was paused by Sandoz, affecting revenue.